IntroductionThis study investigated the promising effect of a new Platelet Glue obtained from Cryoprecipitation of Apheresis Platelet products (PGCAP) used in combination with Mesenchymal Stromal Cells (MSC) loaded on ceramic biomaterials to provide novel strategies enhancing bone repair.MethodsPGCAP growth factor content was analyzed by ELISA and compared to other platelet and plasma-derived products. MSC loaded on biomaterials (65% hydroxyapatite/35% beta-TCP or 100% beta-TCP) were embedded in PGCAP and grown in presence or not of osteogenic induction medium for 21 days. Biomaterials were then implanted subcutaneously in immunodeficient mice for 28 days. Effect of PGCAP on MSC was evaluated in vitro by proliferation and osteoblastic gene expression analysis and in vivo by histology and immunohistochemistry.ResultsWe showed that PGCAP, compared to other platelet-derived products, allowed concentrating large amount of growth factors and cytokines which promoted MSC and osteoprogenitor proliferation. Next, we found that PGCAP improves the proliferation of MSC and osteogenic-induced MSC. Furthermore, we demonstrated that PGCAP up-regulates the mRNA expression of osteogenic markers (Collagen type I, Osteonectin, Osteopontin and Runx2). In vivo, type I collagen expressed in ectopic bone-like tissue was highly enhanced in biomaterials embedded in PGCAP in the absence of osteogenic pre-induction. Better results were obtained with 65% hydroxyapatite/35% beta-TCP biomaterials as compared to 100% beta-TCP.ConclusionsWe have demonstrated that PGCAP is able to enhance in vitro MSC proliferation, osteoblastic differentiation and in vivo bone formation in the absence of osteogenic pre-induction. This clinically adaptable platelet glue could be of interest for improving bone repair.

No abstract

No abstract

No abstract

Results: Ninety-five patients were included in this study. Seventy five underwent EPP, 9 P/D, and 11 P. Of these 95 patients with final diagnosis of MPM, 80 (84.3%) were classified as epithelial and 15 (15.7%) as biphasic. Among the 87 patients classified as MPM of epithelial type after the initial thoracoscopy procedure, 75 (86.2%) were confirmed as a true histological diagnosis and 12 (13.7%) were found to be biphasic at final diagnosis. One patient with a biphasic type at initial diagnostic procedure was found as epithelial type after surgical histological assessment. The sensitivity and specificity values of epithelial diagnosis after thoracoscopy were 94 % and 25 %, respectively, with a positive predictive value of 86 % and a negative predictive value of 37 %. At contrary, the sensitivity and specificity values of biphasic diagnosis after thoracoscopy were 20 % and 98 %, respectively, with a positive predictive value of 75 % and a negative predictive value of 87 %. Conclusions: Thoracoscopy pleural biopsy is confirmed as the cornerstone for the diagnosis of MPM. However this procedure is less efficient in diagnosing histological type as epithelial versus biphasic subtype.